EUVIMEDDescoperă EUVIMED
Open access

Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype

Bryan Q Spring iD, Kohei Watanabe, Megumi Ichikawa, Srivalleesha Mallidi iD, Tatsuyuki Matsudaira, Dmitriy Timerman, Joseph W R Swain, Zhiming Mai, Hiroaki Wakimoto, Tayyaba Hasan

Photochemistry and Photobiology · 2025

DOI: 10.1111/php.13985 ↗

At a glance

Journal article in Photochemistry and Photobiology, 2025. Written by Bryan Q Spring and 9 co-authors. Institution: Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Glioblastoma, Neoplastic Stem Cells, Drug Resistance, Neoplasm, Light. 84 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, Massachusetts General Hospital, Canon Medical Systems USA.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Glioblastoma stem cells (GSCs) are potent tumor initiators resistant to radiochemotherapy, and this subpopulation is hypothesized to re‐populate the tumor milieu due to selection following conventional therapies. Here, we show that 5‐aminolevulinic acid (ALA) treatment—a pro‐fluorophore used for fluorescence‐guided cancer surgery—leads to elevated levels of fluorophore conversion in patient‐derived GSC cultures, and subsequent red light‐activation induces apoptosis in both intrinsically temozolomide chemotherapy‐sensitive and ‐resistant GSC phenotypes. Red light irradiation of ALA‐treated cultures also exhibits the ability to target mesenchymal GSCs (Mes–GSCs) with induced temozolomide resistance. Furthermore, sub‐lethal light doses restore Mes–GSC sensitivity to temozolomide, abrogating GSC‐acquired chemoresistance. These results suggest that ALA is not only useful for fluorescence‐guided glioblastoma tumor resection, but that it also facilitates a GSC drug‐resistance agnostic, red light‐activated modality to mop up the surgical margins and prime subsequent chemotherapy.

Subjects

MeSH terms (MEDLINE)

GlioblastomaNeoplastic Stem CellsDrug Resistance, NeoplasmLightHumansTemozolomideAminolevulinic AcidPhenotypeApoptosisBrain NeoplasmsCell Line, TumorRed Light

Author keywords

cancer stem cellschemosensitizationdrug‐resistanceglioblastomamesenchymalphotodynamic therapy

Substances

TemozolomideAminolevulinic Acid

Authors and institutions

  • Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Physics, Northeastern University, Boston, Massachusetts, USA.
  • Healthcare Optics Research Laboratory, Canon USA, Inc., Cambridge, Massachusetts, USA.
  • Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
  • Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

ORCID profiles: Bryan Q Spring, Srivalleesha Mallidi

Funding

  • NCI NIH HHS
  • Massachusetts General Hospital
  • Canon Medical Systems USA
  • National Cancer Institute

Cite

APA

Spring, B. Q., Watanabe, K., Ichikawa, M., Mallidi, S., Matsudaira, T., Timerman, D., Swain, J. W. R., Mai, Z., Wakimoto, H., & Hasan, T. (2025). Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype. Photochemistry and Photobiology. https://doi.org/10.1111/php.13985

Vancouver

Spring BQ, Watanabe K, Ichikawa M, Mallidi S, Matsudaira T, Timerman D, et al. Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype. Photochemistry and Photobiology. 2025. doi:10.1111/php.13985

BibTeX
@article{Spring2025,
  author = {Spring, Bryan Q and Watanabe, Kohei and Ichikawa, Megumi and Mallidi, Srivalleesha and Matsudaira, Tatsuyuki and Timerman, Dmitriy and Swain, Joseph W R and Mai, Zhiming and Wakimoto, Hiroaki and Hasan, Tayyaba},
  title = {Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype},
  journal = {Photochemistry and Photobiology},
  year = {2025},
  doi = {10.1111/php.13985}
}
Start for free →